Harvard researchers have developed a personalized cancer vaccine tailored to each patient's tumor. Early trials in 21 advanced melanoma patients showed the vaccine is safe and boosts the immune system, activating T-cells to target cancer. If larger trials succeed, this approach could offer a groundbreaking treatment for many cancer patients.